To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan  by Huang, Jing-Wen et al.
Available online at www.sciencedirect.comScienceDirect
Journal of the Chinese Medical Association 78 (2015) 229e234
www.jcma-online.comOriginal Article
To evaluate the treatment response of locally advanced esophageal cancer
after preoperative chemoradiotherapy by FDG-PET/CT scan
Jing-Wen Huang a, Hui-Ling Yeh a,*, Chung-Ping Hsu b, Yu-Yu Lu c, Cheng-Yen Chuang b,
Jin-Ching Lin a, Jai-Fu Lin a, Chen-Fa Chang a
a Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung, Taiwan, ROC
b Division of Thoracic Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, ROC
c Division of Nuclear Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ROC
Received July 4, 2014; accepted October 1, 2014AbstractBackground: This study was designed to gauge the effectiveness of evaluation of tumor response and prognosis by positron emission tomography
with 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) before and after preoperative chemoradiotherapy in patients with
esophageal cancer.
Methods: Forty-nine patients from October 2008 to September 2012 with locally advanced stage esophageal carcinoma, clinical stage T2-4N0-
3M0, who underwent preoperative chemoradiotherapy (preop CRT) followed by esophagectomy were enrolled in our study. All patients un-
derwent two FDG-PET scans to compare those results with the pathologic results. Metabolic response of the primary tumor by the percentage
change of the SUVmax/1 hour (DSUV) before and after preop CRT (DSUV was calculated as the difference between preop CRT SUVmax/1
hour and postop CRT SUVmax/1 hour divided by preop CRT SUVmax/1 hour at esophageal tumor) was evaluated for overall survival (OS),
disease free survival (DFS), local recurrence rate, and distant failure free survival (DFFS). Prognostic factors such as age, different regimen of
chemotherapy, pathologic stage, FDG-PET stage, endoscopic esophageal tumor length, and DSUV were analyzed. The number of highly suspect
malignant lymph nodes was calculated by PET when SUVmax/1 hour 2.5 and by surgical removal. Sensitivity and specificity of regional
lymph node detection by PET were also recorded.
Results: Upon univariate analysis, overall survival rate was related to DSUV >60% ( p ¼ 0.045), pathological N stage ( p ¼ 0.001), and
endoscopic total length of esophageal tumor ( p ¼ 0.005). The result of FDG-PET scan after preop CRT had high specificity (96.7%) but low
sensitivity (45.8%) in predicting the residual malignant lymph node numbers. The positive and the negative prediction rates were 44% and 96%,
respectively. The result of the FDG-PET after preop CRT showed upstaged in 16 patients (32.6%), downstaged in nine patients (18.3%), and the
same stage in 24 patients (48.9%) when compared with the pathologic stage.
Conclusion: The change of SUVmax can be a tool for evaluating tumor response after preop CRT. There is also a trend of good prognosis in
overall survival rate when DSUV value is >60%.
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Esophageal cancer is a very menacing disease with an
extremely poor prognosis because >50% of patients have
unresectable disease at their first presentation in hospital.1
Additionally, long-term survival rate was <35% even after
curative surgery. Nodal involvement is the poorest prognosticociation. All rights reserved.
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have N2 stage or above.2 There was also a high correlation
between the pathologic nodal status and the 2- or 5-year
recurrence rate.3 Although surgery alone is still the main
treatment for early stage esophageal cancer, multidisciplinary
treatment typically provides a superior result for advanced
disease.4 For locally advanced esophageal cancer, preoperative
chemoradiotherapy (preop CRT) followed by esophagectomy
showed benefits in disease-free survival rate and local-regional
control rate compared with surgery alone by a meta-analyses.5
However, elevated 6-month treatment-related mortality was
found in this group.6 Laterza et al7 and Adham et al8 reported
that 5-year survival rates of good responders to neoadjuvant
treatment (downstaging) was 34.9e53% compared with non-
responders (0e10.7%). According to these studies, the sur-
vival rate in good responders was improved by surgery but the
response of chemoradiotherapy is hard to evaluate by con-
ventional imaging, including computed tomography (CT)
scans and endoscopic ultrasound. It is evident that early mo-
lecular or diagnostic markers to screen good responders after
preoperative chemoradiotherapy for curative surgery are ur-
gently needed.
Positron emission tomography (PET) using the radio-
labeled glucose analogue 18F-fluorodeoxyglucose (FDG) as a
tracer is a functional image technique used to differentiate
metabolic changes in normal cells and malignant cells. PET/
CT was used for tumor staging in numerous cancers, such as
colorectal, lung, breast, head and neck cancer, and malignant
lymphomas.9 Furthermore, PET/CT was an independent pre-
dictor of regional lymph node metastasis in patients with Non-
small cell lung cancer (NSCLC), and it has excellent diag-
nostic performance for the overall assessment of distant ma-
lignancies in patients with various cancers, especially head
and neck, breast, and lung cancer.10,11 Imaging through PET/
CT scan also plays an important role in monitoring early re-
sponses to neoadjuvant therapy by scrutinizing the changes of
levels of the standard uptake value (SUV) of the tumor before
and after the treatment.12e14 In this study, we established a
hypothesis that the changes of SUV levels after preop CRT can
be used to predict the good responders for those who will
obtain a benefit from the subsequent curative surgery. We also
undertook analysis of the sensitivity and specificity of PET
scan after preop CRT.
2. Methods2.1. Patient populationFrom October 2008 to September 2012, 49 patients with
locally advanced esophageal carcinoma were enrolled in this
study, clinical stage T2-4N0-3M0, who underwent one of our
preop CRT protocols and subsequent surgical treatment. All
patients were diagnosed by biopsy via esophagoscopy.
Thereafter, patients were excluded from analysis if: (1) distant
metastasis was found by biopsy proven at the time of diag-
nosis; (2) not a candidate for curative surgery due to comor-
bidities or unresectable tumor; (3) other malignant disease forwhich they underwent treatment; or (4) poor liver or renal
function which led to interruption of CRT. All patients un-
derwent a series of preoperative staging procedures, including
physical examinations, laboratory tests, ultrasound of the
abdomen, a barium esophagogram, bronchoscopy, spiral CT
scan of chest and abdomen, a trans-esophageal Endoscopic
ultrasound (EUS), and FDG-PET/CT scanning. The above
procedures were repeated after 3 weeks subsequent to
completion of a preop CRT. All patients provided written
informed consent. Patients who received chemotherapy with
oxaliplatin instead of cisplatin were enrolled from our previ-
ous Phase II clinical trial which was approved by Institutional
Review Board of Taichung Veterans General Hospital.2.2. ChemoradiotherapyThirty patients received Regimen 1: cisplatin 20 mg/m2 iv
for 1 hour plus 5-FU 800 mg/m2 continuous infusion for 24
hours daily when radiotherapy began on Day 1 to Day 4, and
from Day 29 to Day 32. Nineteen patients received Regimen 2
(regimen from our Phase II clinical study with oxaliplatin):
Oxaliplatin 35 mg/m2 iv for 2 hours plus leucovorin 200 mg/
m2 iv for 2 hours and then 5-FU 400 mg/m2 continuous
infusion for 48 hours prior to radiotherapy as loading dose and
then when radiotherapy starts oxaliplatin 45 mg/m2 iv 2 hours
on Day 1 of RT plus 5-FU 400 mg/m2 continuous infusion for
24 hours on Days 1e5 of RT. On Day 15 of RT, oxaliplatin
45 mg/m2 iv for 2 hours and then oxaliplatin 45 mg/m2 iv for 2
hours on Day 29 of RT plus 5-FU 400 mg/m2 continuous
infusion for 24 hours on Days 29e33 of RT.
All patients underwent CT simulation in a supine position
with their arms above their heads, and a customized vacuum
bag was used for immobilization. The CT images were taken
at a 5-mm thickness throughout the neck and the entire thorax
for the upper and the middle thoracic tumors, or the entire
thorax and the abdomen for the lower thoracic tumors. Gross
tumor volume (GTV), clinical target volume (CTV), planning
target volume (PTV), and the organs at risk were outlined on
the CT images. GTV is the gross tumor volume at the
esophagus. CTV included GTV plus a 5 cm margin above and
below the tumor, lymph nodes in the mediastinum and
supraclavicular area (if the tumor was located in the upper or
middle thoracic portion), and celiac trunk region (if the tumor
was located in the lower thoracic portion). A margin of 0.5 cm
was also added to the CTVas PTV to allow for the daily setup
error and organ motion.
The IMRT plan using multiple field technique was deliv-
ered to each patient by a linear accelerator (Varian 2100EX
with a 120-leaf Millennium multileaf collimator, Varian
Oncology Systems, Palo Alto, CA, USA) using 6 MV photons.
Dose calculations were performed using the Varian Eclipse
planning system (versions 6.5e7.2.24) (Varian Medical Sys-
tems Inc., Worldwide Headquarters 3100 Hansen Way, Palo
Alto, CA94304, USA) based on the pencil beam model. A
total dose of 45e50.4 Gy was prescribed to the PTV in such a
way that 95% of PTV was receiving 100% of the prescribed
dose. The dosage constraints for organ-at-risk (OAR) were
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receive >20Gy (V20), and <67% for heart volume that receive
>45Gy (V45), and <50Gy for the total spinal cord. Radio-
therapy was performed 5 days per week, with a daily dose of
180 Gy for a total course of 5e6 weeks.2.3. SurgeryAfter radiation therapy was complete, surgery was per-
formed 3e5 weeks later. The surgical procedure which was
undertaken included thoracoscopic esophagectomy and
esophagus reconstruction with gastric tube by laparotomy over
the upper midline. The gastric tube was pushed through the
retrosternal tract in the anatomic plane with the correct axis
and was thereafter adequately mobilized. Besides, extended
lymph node dissection including mediastinal lymph nodes
(Group 2, Group 4, Group 7, Group 8, and other enlarged
lymph nodes suspected to be malignant) and bilateral recurrent
laryngeal lymph nodes were removed by the Chest Surgery
(CS) doctor. Furthermore, radical neck lymph nodes dissection
was performed by the Ear, Nose and Throat (ENT) doctor if
indicated. Any abnormal operation finding such as suspected
peritoneal seeding or liver metastasis was recorded and
removed if possible.2.4. Tumor regression gradingTumor regression grade (TRG) was quantitated into five
grades: TRG 1 (complete regression) showed absence of re-
sidual cancer and fibrosis extending through the different
layers of the esophageal wall; TRG 2 was characterized by the
presence of rare residual cancer cells scattered through the
fibrosis; TRG 3 was characterized by an increase in the
number of residual cancer cells, but fibrosis still predomi-
nated; TRG 4 showed residual cancer outgrowing fibrosis; and
TRG 5 was characterized by an absence of regressive
changes.15 Pathological responders included TRG 1 and TRG
2, and nonresponders were TRG 3e5.2.5. PET/CT techniqueForty-nine patients underwent PET/CT examinations which
were performed on a Philips Health care Gemini TF (General
Electric Advance Nxi, General Electric Medical Systems,
Milwaukee, WI, USA) dedicated PET/CT system. The pro-
tocol used for the PET scan required patients to fast for 8
hours prior to the administration of 18F-FDG (5 MBq/kg, up to
a maximum of 550MBq), and blood glucose levels were
required to be 150 mg/dL.18F-FDG was injected into an
antecubital vein, and then PET imaging was initiated after a
60-minute uptake period. PET data were reconstructed using a
three-dimensional (3D) acquisition in 10e12 bed positions for
1 minute per bed. Scans were acquired from the base of the
skull to the upper thighs for all patients. PET/CT images were
interpreted visually plus semiqualitatively. The maximum
SUV value within this was recorded as the SUVmax. Addi-
tionally, the SUVmax of preop CRT and postoperativechemoradiotherapy (postop CRT) at the primary esophageal
tumor were also recorded for analysis. Lymph nodes were
considered as malignant by a PET scan image when the SUV
level for max/1 hour 2.5.16 The cut-off value of the primary
esophageal tumor varies due to postop CRT inflammation, but
a single foci of elevated SUV value was be recorded and
considered residual tumor. Sensitivity was defined as true
positive lymph nodes (where PET showed positive findings
and was proven by pathology) divided by positive pathology.
Specificity was defined as true negative lymph nodes (PET
showed negative findings and was proven by pathology)
divided by negative pathology. The percentage of tumor
downstaging or upstaging by PET was calculated.
FDG-PET/CT scan was performed prior to any treatment
and 3 weeks after preop CRT. The primary tumor stage and
nodal stage after preop CRT by FDG-PET scan were then
analyzed by a pathologist for histopathological validation.
Afterwards, a number of suspected malignant lymph nodes
from the postop CRT FDG-PET/CT scan were evaluated using
standard tools to arrive at the pathologic findings. Metabolic
response of the primary esophageal tumor after preop CRT
was assessed by DSUV. DSUV was calculated as the differ-
ence between preop CRT SUVmax/1 hour and postop CRT
SUVmax/1 hour divided by preop CRT SUVmax/1 hour at the
esophageal tumor. The correlation of DSUV between overall
survival (OS), local failure free survival (LFFS), disease free
survival (DFS), and distant failure free survival (DFFS) were
calculated. Prognostic factors such as age, different regimen of
chemotherapy, pathology stage of T, N, PET stage, endoscopic
tumor length, preop CRT SUV, postop CRT SUV, and DSUV
were also analyzed.2.6. Statistical analysisKaplaneMeier curves were used to describe survival for
each stage group as defined by both pathologic and FDG-PET/
CT stages. We also used log-rank tests to compare the survival
curves. The Cox proportional hazards regression model was
used to estimate the hazard ratios and confidence intervals. A p
value <0.05 was considered statistically significant. Sensi-
tivity, specificity, positive predicted value, and negative pre-
dicted value were determined for CT, EUS-FNA, and FDG-
PET/CT by using the pathology.
3. Results
Forty-nine patients (male/female ratio 48/1) with squamous
cell carcinoma (95.9%) and adenocarcinoma (4.1%) were
enrolled in this study. All underwent preoperative CRT
including a regimen of cisplatin plus 5-FU (30 patients) or
oxaliplatin plus 5-FU (19 patients) and subsequent surgical
treatment. Initial tumor stage and other characteristics of the
patients are described in Table 1.
Pathologic complete response (pT0N0) was 28.5% (14
patients), partial tumor response was 65.3% (32 patients),
stable disease was 4% (2 patients), and progression disease
was 2% (1 patient). Mean overall survival time was 17.3
Table 1
Clinical characteristics of patients.
Age (y)
Median 53
Sex n
Male 48
Female 1
Clinical stage
T stage
T2 1
T3 48
N stage
N0 5
N1 28
N2 16
Histology
Squamous cell carcinoma 47
Adenocarcinoma 2
Chemotherapy regimen
Cisplatinþ5-FU 30
Oxaliplatinþ5-FU 19
Fig. 2. Disease free survival rate for DSUV >60% and DSUV 60%,
p ¼ 0.046. SUV ¼ standard uptake value.
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survival rate (DFS), and distant failure free survival (DFFS)
were 56.8%, 55.2%, and 69.8%, respectively. The 3-year cu-
mulative incidence rate of local recurrence was 8.8%. On
univariate analysis, overall survival rate was related to DSUV
>60% at the esophageal tumor (25 patients, 51%; p ¼ 0.045;
Fig. 1), pathological nodal stage after operation ( p ¼ 0.001),
and endoscopic total length of esophageal tumor ( p ¼ 0.005).
The group of DSUV >60% also showed statistical significance
in disease-free survival rate ( p ¼ 0.046; Fig. 2), and non-
significance in local recurrence rate ( p ¼ 0.378). Other factors
such as age, different regimen of chemotherapy, pathologic T
stage, pre and postop CRT PET stage, preop CRT SUV, and
postop CRT SUV showed no statistical significance in OS, LC,
DFS, and DFFS. On multivariate analysis, there was a statis-
tically significant relationship in the overall survival rate with
pathological nodal stage and endoscopic total length of pri-
mary tumor.
The total number of mediastinum lymph nodes that were
resected was 1373. Additionally, the number of malignant
lymph nodes defined by PET was 75 and benign lymph nodesFig. 1. Overall survival rate for DSUV >60% and DSUV 60%, p ¼ 0.045.
SUV ¼ standard uptake value.was 1298 (inclusive of those lymph nodes which SUVmax
<2.5 and nonmalignant proven by pathology). The specificity
and sensitivity of PET/CT in predicting malignant lymph node
numbers were 96.7% and 45.8%, respectively. The positive
predictive value was 44% and negative predictive value was
96.9% for Nodal staging (Table 2). By comparing with PET
staging after preop CRT and the actual tumor, preop results
were upstaged in 16 patients (32.6%), downstaged in 9 pa-
tients (18.3%), and were the same stage in 24 patients (48.9%)
by pathologic staging.
4. Discussion
Preoperative CRT followed by curative surgery gives an
improved survival rate for the good tumor responder (TRG1
and TRG2). In order to best evaluate the tumor response, EUS
can be used for the assessment of the extent of mucosal
involvement and peritumoral nodal metastases. However, the
information may be limited in cases of obstructive esophageal
cancer where passage of the endoscope may not be feasible.
CT scanning provides a superior assessment in regional
lymphadenopathy such as mediastinum lymph nodes and
metastasis disease but CT scanning is less sensitive in the
detection of local regional or distant metastasis.17 FDG-PET
using the radiolabeled glucose analogue 18F-fluorodeox-
yglucose (FDG) as a tracer provides a functional image of the
tumor and thus can be used in tumor staging. PET combined
with CT (PET/CT) provides not only functional but alsoTable 2
Predictive value of nodal staging by PET.
PET Pathologya,b
Positive Negative
Positive 33 42
Negative 39 1259
PPV ¼ 0.44.
NPV ¼ 0.96.
a Sensitivity ¼ 0.45 (true positive/pathology positive).
b Specificity ¼ 0.96 (true negative/pathology negative).
PET ¼ positron emission tomography; NPV ¼ negative predictive value;
PPV ¼ positive predictive value.
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value (SUVmax) is a marker of tumor glucose metabolism
detected by PET/CT, which reflects the aggressiveness of
tumor behavior. A meta-analysis study also used the difference
of SUV to predict response, and the DSUV percentages ranged
from 35% to 63%.18 The result of our study showed a strong
relationship between DSUV >60% and overall patient sur-
vival. The 3-year overall survival rate of DSUV >60% was
71%, and was 40.7% in the group of DSUV 60%. From our
results, preop CRTwith cisplatin plus 5-FU or oxaliplatin plus
5-FU seemed to be a reasonable regimen and showed slightly
better survival (mean overall survival time: 17.3 months)
compared with previous studies (13.3e16.8 months; INT 0113
and MRC trials). For this reason, we used DSUV to evaluate
treatment response in this study and overall survival rate was
related to DSUV >60% ( p ¼ 0.045). This data can be used to
differentiate whether or not patients were responsive to che-
moradiotherapy. Furthermore, the surgeon can also get infor-
mation about which patients will benefit from curative
surgery.19
Hu et al20 showed that SUVmax had a positive correlation
with tumor proliferative activity. Sun et al21 showed that SUV
max had no significant value in evaluation of prognosis of
esophageal cancer by FDG-PET. Similar to Sun et al's21 study,
pre- and postop CRT absolute value of SUVmax showed no
statistical significance in overall survival rate in our study. The
pre- or postop CRT SUV max was still questionable in pre-
dicting the prognosis. The number and quality of studies
included in each analysis might be different, which might
affect the indirect comparison of results at the different PET
scan time. The histology type of these studies was predomi-
nantly adenocarcinoma, which was not suitable to our region
(squamous was the most frequently seen histology type, which
was reflected in our study results, SCC: 95.9%). Besides, these
data lacked standardization of the acquisition and processing
protocols. In our study, all FDG-PET/CT were performed 3
weeks after preop CRT and standardized by the same protocol.
According to a randomized trial,6 therapeutic strategies
with or without surgery result in similar survival rates for
locally advanced thoracic esophageal cancer patients (espe-
cially for patients with epidermoid tumors) responding to
chemoradiation. However, another study22 suggested that
adding surgery to chemoradiotherapy improves local tumor
control. But surgery does not increase the overall survival rate
in this group. Our goal of improving the survival duration can
be achieved by separating the good responders to preop CRT
from the poor responders. In this study, using the change of
SUVmax level can assist us in evaluating treatment responses.
The pathologic N stage was an important prognostic factor
of overall survival rate. FDG-PET/CT can also provide infor-
mation regarding the prediction of lymph node status, and it
can also be an indirect tool of evaluating prognosis. We tried to
use FDG-PET/CT as a noninvasive, relatively high specificity
and sensitivity tool to predict who was responsive to preop
CRT. In this study, preoperative PET had high specificity
(96.7%) but low sensitivity (45.8%) in predicting negative
malignant lymph node numbers. For this reason, there were 16patients (32.6%) who were upstaged by PET staging. This high
specificity and low sensitivity in predicting the elevated pos-
sibility of pathologic N0 if no SUVmax of lymph nodes were
>2.5 implies a better survival rate for N0 than for those patients
who are node positive. The sensitivity and specificity in one
study by FDG-PET/CTwas 63% and 100%, respectively.23 But
Cerfolio et al23 showed that the most prevalent histology type
was adenocarcinoma (85%), and that all patients had N1 dis-
ease before preop CRT. Also, the cut-off SUVmax value in that
study was similar to our study (2.5). However, that study also
analyzed the sensitivity and specificity of CT and EUS, which
were 13% and 94%, respectively. Thus, FDG-PET/CT was a
better tool in evaluating mediastinum lymph nodes.
There were several limitations for the evaluation of tumor
response by FDG-PET/CT scan in our study. Firstly, physio-
logical FDG uptake of the normal esophagus was hard to
differentiate from the inflammatory esophagus after CRT.
Thus, postop CRT SUVmax was defined as background FDG
uptake if no significant higher uptake in single foci was found.
Accordingly, there could be a bias when calculating DSUV.
Secondly, the pre and postop CRT tumor invasion range was
hard to evaluate due to the characteristics of FDG-PET.
Thirdly, a low sensitivity but high specificity in detecting
regional lymph nodes indicated that PET has its limitation in
the detection of mediastinum lymph nodes. Fourthly, to eval-
uate the preop CRT N stage by PET was difficult to define due
to some cluster lymph nodes which could not be precisely
calculated. The ability to evaluate tumor responses after preop
CRT by PET-CT thus offers another choice for those patients
who will not achieve any benefit from surgery and will suffer
an increased risk of mortality. For these reasons, the PET scan
is a good tool for evaluating the treatment response and a good
prognostic factor although some disadvantages were noted.
In conclusion, the level of DSUV >60% was found to be of
significant predictive value for pathologic response and sur-
vival in patients with esophageal carcinoma who undergo
preoperative CRT on univariate analysis. Thus, this subgroup
may obtain benefits from subsequent curative surgery. Preop-
erative PET had a high specificity but a lack of sensitivity in
the evaluation of negative pathologic node stage.References
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